- MedMen terminated its $682 million merger with PharmaCann on Tuesday, in a move one analyst called ‘surprising.’
- The merger’s cancellation points to a challenging dealmaking environment in the cannabis industry, as the sector has declined close to 50% in the past few months.
- Business Insider spoke to lawyers, bankers, and analysts who work with cannabis companies about what this means for the industry.
- Click here for more BI Prime stories and subscribe to our weekly cannabis newsletter, Cultivated.
It’s been a tough week for publicly traded cannabis companies, capping off a difficult few months for the sector.
In a surprise move read more >>>